Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471078 · ClinicalTrials.gov registry record · Phase 3
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
A Phase 3 study, sponsored by Sobi.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT03471078 is a Phase 3 study that has completed, run by Sobi. The registered enrollment target is 122 participants.
The verdict
NCT03471078, a Phase 3 study, has completed, sponsored by Sobi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Avatrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-10-12 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03471078
The ClinicalTrials.gov registry entry for NCT03471078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sobi, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03471078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03471078 about?
NCT03471078 is a clinical study titled "Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers". Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.
What is the current status of trial NCT03471078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2018-10-12. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT03471078?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Avatrombopag (DRUG).
Who is sponsoring clinical trial NCT03471078?
This trial is sponsored by Sobi, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.